The WOC Skin Health Weekly®, a weekly e-news publication packed with career empowerment resources including the latest clinical, industry, and product news, clinical education, market research, and of course, the most recently posted jobs requiring expertise in the prevention and treatment of skin breakdown and wound care. Over 20,000 clinicians now receive the WOC Skin Health Weekly.
Receive your own complimentary subscription to the WOC Skin Health Weekly®
Ensuring at-risk residents receive the proper equipment, and care, for preventing or treating pressure injuries is critical to not only the health of the resident, but also to the health of your facility’s bottom line and reputation. Register Now
Pressure injuries affect 2.5 million residents, lead to 60,000 deaths and cost $9 to $11.6 billion per year in the United States, according to the Agency for Healthcare Research and Quality. Moreover, pressure injuries are painful and detrimental to patient quality of life. People who acquire pressure injuries face an average of five extra days in the hospital, according to the National Medicare Patient Safety Monitoring System Study. The study also shows 22 percent are readmitted to the hospital within 30 days of discharge Read More
A research team led by UCLA biomolecular engineers and doctors has demonstrated a therapeutic material that could one day promote better tissue regeneration following a wound or a stroke. During the body's typical healing process, when tissues like skin are damaged the body grows replacement cells. Integrins are class of proteins that are important in the cellular processes critical to creating new tissue. One of the processes is cell adhesion, when new cells "stick" to the materials between cells, called the extracellular matrix Read More
The first patient has been dosed in a Phase III trial assessing ViroMed's VM202, the first pivotal study of a gene therapy indicated for patients with nonhealing diabetic foot ulcers (NHU) and concomitant peripheral artery disease (PAD). The Phase III trial is a double-blind, placebo-controlled, multicenter study designed to evaluate VM202 for safety and efficacy in 300 adults with a diabetic foot ulcer and concomitant PAD. Two hundred patients will be randomized to VM202 and the other 100 to placebo. Patients will receive ongoing wound care for the duration of the trial, the company added. Read More